The U.S. Preventative Services Task Force (USPSTF) recommendation against the use of Prostate-Specific Antigen (PSA) blood tests sets a dangerous precedent for all patients seeking preventative measures in the fight against cancer. Prostate cancer is the most common form of the disease, representing one quarter of all new cases diagnosed annually in Canada. A PSA test is the most common tool to detect prostate cancer
Remembering Maureen By Jackie Manthorne Maureen died on May 17, 2012 after a valiant battle with pulmonary fibrosis. She was the loving mother of Natalie and her husband Brent Pilon, and Steve Kelly. She was the very proud and doting grandmother of Chloe Pilon and Mark and Ashley Dempsey. She was the beloved sister of Patricia McPoland and John McPoland, and was predeceased by her
This is a reminder of the upcoming town hall meetings near you. As you know, the recent “austerity budget” threatens more cuts to hospitals and health services all across Ontario. All concerned citizens are asked to take part in learning about cuts and their impact on local communities and to get involved in the fight to stop cuts to health care. To date, the town
Provinces are fifth and sixth in Canada to reimburse new metastatic prostate cancer treatment Toronto, ON (May 16, 2012) – Men living with metastatic prostate cancer in Nova Scotia and Newfoundland and Labrador now have access to a new treatment option, as these provinces have made the decision to include ZYTIGA® (abiraterone acetate) on their public formularies for the treatment of metastatic, castration-resistant prostate cancer.
First Oral Treatment for Metastatic Prostate Cancer That Inhibits Androgen Production at All Three Sources Toronto, ON, July 28, 2011– Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), an oral medication for the treatment of men with metastatic prostate cancer. ZYTIGA™ is indicated with prednisone for the treatment of men with metastatic prostate cancer (castration-resistant prostate cancer)
Patients with advanced prostate cancer gain access to first-in-class treatment OTTAWA, April 25, 2012 /CNW/ – Canadian Cancer Survivor Network (CCSN) is today congratulating the Ontario government for providing access to XGEVA® (denosumab) for the prevention of debilitating bone complications, known as skeletal-related events (SREs), in men with advanced prostate cancer which has spread to the bone. When cancer metastasizes to the bone, a number of serious